PGE1 is produced by the metabolism of dihomo-γ-linolenic acid （DGLA） by the cyclooxygenase pathway. PGE1 inhibits platelet aggregation （IC50 = 40 nM） and increases vasodilation.13，14-dihydro-16，16-difluoro PGE1 is a biologically active metabolite of PGE1， inhibiting platelet aggregation with comparable potency to the parent compound. The addition of two electron-withdrawing fluorine atoms， which should stabilize the molecule against hydrolytic cleavage， may be expected to delay degradation in vivo. 13，14-dihydro-15（R，S）-hydroxy-16，16-difluoro PGE1-3，3’，4，4’-d4） contains four deuterium atoms at the 3， 3’， 4， and 4’ positions. It is intended for use as an internal standard for the quantification of 13，14-dihydro-15（R，S）-hydroxy-16，16-difluoro Prostaglandin E1 by GC- or LC-mass spectrometry （MS）.
产品描述
An internal standard for quantification of 13，14-dihydro-15 （R，S）-hydroxy-16，16-difluoro-Prostaglandin E1， a metabolite of a bicyclic PGE1 derivative used in the treatment of chronic constipation， by GC- or LC-mass spectrometry （MS）
